SCHEMBL1965084

SCHEMBL1965084

CC(C)(C)OC(=O)N(Cc1ccc2ccccc2c1)n1cccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 1/20 0.40
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
SLC6A2 P23975 4/20 0.39
SLC6A4 P31645 4/20 0.39
SLC6A3 Q01959 3/20 0.39
MC4R P32245 1/20 0.38
MC3R P41968 1/20 0.38
KCNH2 Q12809 2/20 0.37
LSS P48449 1/20 0.37
PYCR1 P32322 1/20 0.37
ACHE P22303 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
PTPN1 P18031 1/20 0.37
NR1H2 P55055 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1964950 0.84 AKT1 (0.46) CTSBCTSSSLC6A4HDAC3HDAC1
SCHEMBL1965931 0.82 L3MBTL1 (0.43) ACHEMEN1KMT2A
SCHEMBL1966131 0.81 KDM1A (0.42) HDAC3HDAC1HDAC2HDAC8MEN1
SCHEMBL1965400 0.81 GAA (0.40) LSSHDAC3HDAC1HDAC2MEN1
SCHEMBL1965544 0.80 RIPK1 (0.47) CTSSCTSKMEN1KMT2A
SCHEMBL1965890 0.80 RIPK1 (0.47) SLC6A4PYCR1KMT2A
SCHEMBL1966228 0.79 MEN1 (0.41) KCNH2LSSPYCR1HDAC3HDAC1
SCHEMBL1966223 0.78 ALDH1A1 (0.42) MEN1KMT2A
SCHEMBL1964210 0.75 RIPK1 (0.46) CTSSCTSKPTPN1MEN1KMT2A
SCHEMBL1966140 0.75 NPC1 (0.39) PYCR1ACHEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 CTSB 1103/4885CTSS 1563/4885CTSK 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.